10 Biotech Stocks Screaming a Buy

6. ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)

Year to Date Gain as of June 18: 22.19%

Number of Hedge Fund Holders as of Q1: 35

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) is one of the 10 biotech stocks screaming a buy. On June 17, the company moved to attract and retain top talent by granting inducement awards to 41 employees. Under the 2024 Inducement Plan, the company will award the employees non-qualified stock options of 187,664 shares and 89.582 restricted stock units designed to attract and retain talent.

The move to offer inducement awards is part of Acadia Pharmaceuticals’ push to secure top-skilled professionals essential for its neuroscience projects. It expects the awards to ensure employees are incentivized to contribute to the long-term objectives expected to lead to sustained growth and innovation.

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) is a biopharmaceutical company focused on developing and commercializing therapies for central nervous system (CNS) disorders and rare diseases. It works on Parkinson’s disease psychosis and Rett syndrome treatment, with marketed products like NUPLAZID (pimavanserin) and DAYBUE.